Here is the slide deck from this evenings NKTR-214 ASCO presentation for review:
The patient response data cut is from May 29th, so this is the current up to date data on PIVOT.
My prelim review is that all three malignancies (stage IV melanoma, Stage IV RCC (renal), and stage IV NSCLC (Nonsmall cell lung CA) show deepening response rates over time, spread over the cohort (which is relatively small, 11, 14, and 5 patients respectively). In fact, one patient in the RCC cohort and one patient in the melanoma cohort have achieved complete clinical remission and are therefore off study. This is as close to cured as you can get. There are too few patients in the NSCLC cohort to make a statistically significant judgement as whether to proceed to Phase 2. This is probably only a matter of time.
Note that not all patients are responders, with a few progressing despite therapy, but the majority show deepening response over time. Several of the patients have showed diminished tumor bulk of near 100%, with others over 50%, with very few patients coming off therapy due to adverse effects.
Now enrolling and expanding phase 2 for RCC, melanoma, and urothelial CA…